Director/PDMR Shareholding

RNS Number : 1314V

Mediclinic International plc

05 August 2022

 

Mediclinic International plc

(Incorporated in England and Wales)

Company Number: 08338604

LSE Share Code: MDC

JSE Share Code: MEI

NSX Share Code: MEP

ISIN: GB00B8HX8Z88

LEI: 2138002S5BSBIZTD5I60

South African income tax number: 9432434182

('Mediclinic', the 'Company', or the 'Group')

5 August 2022

NOTIFICATION: TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES & PERSONS CLOSELY ASSOCIATED WITH THEM

This notification sets out the details of awards over ordinary shares in Mediclinic ('Shares') granted to directors and other persons discharging managerial responsibilities ('PDMRs') on 5 August 2022 under the Company's short-term incentive scheme ('STI') and long-term incentive plan ('LTIP'), in accordance with the Remuneration Policy and share plan rules approved by shareholders at the annual general meeting of the Company held on 28 July 2022.

Name	Director/ PDMR	Number of Shares awarded under the STI	Number of Shares awarded under the LTIP
Dr Carel Aron van der Merwe	Director	74 718	237 716
Petrus Jurgens Myburgh	Director	47 488	148 319
David John Hadley	PDMR	n/a	58 369
Gert Cornelis Hattingh	PDMR	n/a	28 716
Dr Dirk Cornelius le Roux	PDMR	n/a	22 450
Dr Daniel Liedtke	PDMR	n/a	52 074
Magnus Oetiker	PDMR	n/a	51 945
Koert Hendrik Stefanus Pretorius	PDMR	n/a	30 055
Dr René Toua	PDMR	n/a	23 594
Dr Tyson Bruno Welzel	PDMR	n/a	40 608
Greg van Wyk	PDMR	n/a	27 270

The above awards were granted for nil consideration and are based on the closing price of a Share on 4 August 2022, which equates to £4.98 per Share.

1.	Details of PDMR / person closely associated with them
a)	Name	Dr Carel Aron van der Merwe
2.	Reason for the notification
a)	Position / status	Group Chief Executive Officer - Mediclinic International plc
b)	Initial notification / amendment	Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Mediclinic International plc
b)	LEI	2138002S5BSBIZTD5I60
4.1	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification Code	Ordinary Shares GB00B8HX8Z88
b)	Nature of the transaction	Award over ordinary shares in Mediclinic International plc granted at nil cost under the Company's Short-Term Incentive scheme
c)	Price(s) and volume(s)	Price(s) Volume(s) £nil 74 718
d)	Aggregated information Aggregated volume Price	74 718 £nil
e)	Date of the transaction	5 August 2022
f)	Place of the transaction	Outside a trading venue
4.2	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification Code	Ordinary Shares GB00B8HX8Z88
b)	Nature of the transaction	Award over ordinary shares in Mediclinic International plc granted at nil cost under the Company's Long-Term Incentive Plan
c)	Price(s) and volume(s)	Price(s) Volume(s) £nil 237 716
d)	Aggregated information Aggregated volume Price	237 716 £nil
e)	Date of the transaction	5 August 2022
f)	Place of the transaction	Outside a trading venue

1.	Details of PDMR / person closely associated with them
a)	Name	Petrus Jurgens Myburgh
2.	Reason for the notification
a)	Position / status	Group Chief Financial Officer - Mediclinic International plc
b)	Initial notification / amendment	Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Mediclinic International plc
b)	LEI	2138002S5BSBIZTD5I60
4.1	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification Code	Ordinary Shares GB00B8HX8Z88
b)	Nature of the transaction	Award over ordinary shares in Mediclinic International plc granted at nil cost under the Company's Short-Term Incentive scheme
c)	Price(s) and volume(s)	Price(s) Volume(s) £nil 47 488
d)	Aggregated information Aggregated volume Price	47 488 £nil
e)	Date of the transaction	5 August 2022
f)	Place of the transaction	Outside a trading venue
4.2	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification Code	Ordinary Shares GB00B8HX8Z88
b)	Nature of the transaction	Award over ordinary shares in Mediclinic International plc granted at nil cost under the Company's Long-Term Incentive Plan
c)	Price(s) and volume(s)	Price(s) Volume(s) £nil 148 319
d)	Aggregated information Aggregated volume Price	148 319 £nil
e)	Date of the transaction	5 August 2022
f)	Place of the transaction	Outside a trading venue

1.	Details of PDMR / person closely associated with them
a)	Name	David John Hadley
2.	Reason for the notification
a)	Position / status	Chief Executive Officer - Mediclinic Middle East
b)	Initial notification / amendment	Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Mediclinic International plc
b)	LEI	2138002S5BSBIZTD5I60
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification Code	Ordinary Shares GB00B8HX8Z88
b)	Nature of the transaction	Award over ordinary shares in Mediclinic International plc granted at nil cost under the Company's Long-Term Incentive Plan
c)	Price(s) and volume(s)	Price(s) Volume(s) £nil 58 369
d)	Aggregated information Aggregated volume Price	58 369 £nil
e)	Date of the transaction	5 August 2022
f)	Place of the transaction	Outside a trading venue

1.	Details of PDMR / person closely associated with them
a)	Name	Gert Cornelis Hattingh
2.	Reason for the notification
a)	Position / status	Group Chief Governance Officer - Mediclinic International plc
b)	Initial notification / amendment	Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Mediclinic International plc
b)	LEI	2138002S5BSBIZTD5I60
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification Code	Ordinary Shares GB00B8HX8Z88
b)	Nature of the transaction	Award over ordinary shares in Mediclinic International plc granted at nil cost under the Company's Long-Term Incentive Plan
c)	Price(s) and volume(s)	Price(s) Volume(s) £nil 28 716
d)	Aggregated information Aggregated volume Price	28 716 £nil
e)	Date of the transaction	5 August 2022
f)	Place of the transaction	Outside a trading venue

1.	Details of PDMR / person closely associated with them
a)	Name	Dr Dirk Cornelius le Roux
2.	Reason for the notification
a)	Position / status	Group Chief Information Officer - Mediclinic International plc
b)	Initial notification / amendment	Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Mediclinic International plc
b)	LEI	2138002S5BSBIZTD5I60
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification Code	Ordinary Shares GB00B8HX8Z88
b)	Nature of the transaction	Award over ordinary shares in Mediclinic International plc granted at nil cost under the Company's Long-Term Incentive Plan
c)	Price(s) and volume(s)	Price(s) Volume(s) £nil 22 450
d)	Aggregated information Aggregated volume Price	22 450 £nil
e)	Date of the transaction	5 August 2022
f)	Place of the transaction	Outside a trading venue

1.	Details of PDMR / person closely associated with them
a)	Name	Dr Daniel Liedtke
2.	Reason for the notification
a)	Position / status	Chief Executive Officer: Hirslanden
b)	Initial notification / amendment	Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Mediclinic International plc
b)	LEI	2138002S5BSBIZTD5I60
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification Code	Ordinary Shares GB00B8HX8Z88
b)	Nature of the transaction	Award over ordinary shares in Mediclinic International plc granted at nil cost under the Company's Long-Term Incentive Plan
c)	Price(s) and volume(s)	Price(s) Volume(s) £nil 52 074
d)	Aggregated information Aggregated volume Price	52 074 £nil
e)	Date of the transaction	5 August 2022
f)	Place of the transaction	Outside a trading venue

1.	Details of PDMR / person closely associated with them
a)	Name	Magnus Oetiker
2.	Reason for the notification
a)	Position / status	Group Chief Strategy Officer - Mediclinic International plc
b)	Initial notification / amendment	Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Mediclinic International plc
b)	LEI	2138002S5BSBIZTD5I60
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification Code	Ordinary Shares GB00B8HX8Z88
b)	Nature of the transaction	Award over ordinary shares in Mediclinic International plc granted at nil cost under the Company's Long-Term Incentive Plan
c)	Price(s) and volume(s)	Price(s) Volume(s) £nil 51 945
d)	Aggregated information Aggregated volume Price	51 945 £nil
e)	Date of the transaction	5 August 2022
f)	Place of the transaction	Outside a trading venue

1.	Details of PDMR / person closely associated with them
a)	Name	Koert Hendrik Stefanus Pretorius
2.	Reason for the notification
a)	Position / status	Group Chief Operating Officer - Mediclinic International plc
b)	Initial notification / amendment	Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Mediclinic International plc
b)	LEI	2138002S5BSBIZTD5I60
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification Code	Ordinary Shares GB00B8HX8Z88
b)	Nature of the transaction	Award over ordinary shares in Mediclinic International plc granted at nil cost under the Company's Long-Term Incentive Plan
c)	Price(s) and volume(s)	Price(s) Volume(s) £nil 30 055
d)	Aggregated information Aggregated volume Price	30 055 £nil
e)	Date of the transaction	5 August 2022
f)	Place of the transaction	Outside a trading venue

1.	Details of PDMR / person closely associated with them
a)	Name	Dr René Toua
2.	Reason for the notification
a)	Position / status	Group Chief Clinical Officer - Mediclinic International plc
b)	Initial notification / amendment	Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Mediclinic International plc
b)	LEI	2138002S5BSBIZTD5I60
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification Code	Ordinary Shares GB00B8HX8Z88
b)	Nature of the transaction	Award over ordinary shares in Mediclinic International plc granted at nil cost under the Company's Long-Term Incentive Plan
c)	Price(s) and volume(s)	Price(s) Volume(s) £nil 23 594
d)	Aggregated information Aggregated volume Price	23 594 £nil
e)	Date of the transaction	5 August 2022
f)	Place of the transaction	Outside a trading venue

1.	Details of PDMR / person closely associated with them
a)	Name	Dr Tyson Bruno Welzel
2.	Reason for the notification
a)	Position / status	Group Chief Innovation Officer - Mediclinic International plc
b)	Initial notification / amendment	Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Mediclinic International plc
b)	LEI	2138002S5BSBIZTD5I60
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification Code	Ordinary Shares GB00B8HX8Z88
b)	Nature of the transaction	Award over ordinary shares in Mediclinic International plc granted at nil cost under the Company's Long-Term Incentive Plan
c)	Price(s) and volume(s)	Price(s) Volume(s) £nil 40 608
d)	Aggregated information Aggregated volume Price	40 608 £nil
e)	Date of the transaction	5 August 2022
f)	Place of the transaction	Outside a trading venue

1.	Details of PDMR / person closely associated with them
a)	Name	Greg van Wyk
2.	Reason for the notification
a)	Position / status	Chief Executive Officer: Mediclinic Southern Africa
b)	Initial notification / amendment	Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Mediclinic International plc
b)	LEI	2138002S5BSBIZTD5I60
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification Code	Ordinary Shares GB00B8HX8Z88
b)	Nature of the transaction	Award over ordinary shares in Mediclinic International plc granted at nil cost under the Company's Long-Term Incentive Plan
c)	Price(s) and volume(s)	Price(s) Volume(s) £nil 27 270
d)	Aggregated information Aggregated volume Price	27 270 £nil
e)	Date of the transaction	5 August 2022
f)	Place of the transaction	Outside a trading venue

About Mediclinic International plc

Mediclinic is a diversified international private healthcare services group, established in South Africa in 1983, with divisions in Switzerland, Southern Africa (South Africa and Namibia) and the Middle East.

The Group's core purpose is to enhance the quality of life.

Its vision is to be the partner of choice that people trust for all their healthcare needs.

Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the continuum of care in such a way that the Group will be regarded as the most respected and trusted provider of healthcare services by patients, medical practitioners, funders and regulators of healthcare in each of its markets.

At 30 June 2022, Mediclinic comprised 74 hospitals, five subacute hospitals, two mental health facilities, 20 day case clinics and 23 outpatient clinics. The Swiss operations included 17 hospitals and four day case clinics with around 1 900 inpatient beds; Southern Africa operations included 50 hospitals (three of which in Namibia), five subacute hospitals, two mental health facilities and 14 day case clinics (four of which operated by Intercare) across South Africa, and around 8 650 inpatient beds; and the Middle East operated seven hospitals, two day case clinics and 23 outpatient clinics with around 1 000 inpatient beds in the UAE. In addition, under management contract the Middle East will open a 200-bed hospital in the Kingdom of Saudi Arabia in 2023.

The Company's primary listing is on the London Stock Exchange ("LSE") in the United Kingdom, with secondary listings on the JSE in South Africa and the Namibian Stock Exchange in Namibia.

Mediclinic also holds a 29.7% interest in Spire Healthcare Group plc, a leading private healthcare group based in the United Kingdom and listed on the LSE.

For further information, please contact:

Company Secretary, Link Company Matters Limited

Caroline Emmet

[phone]

Investor Relations

James Arnold, Head of Investor Relations

[e-mail]

[phone]

Media queries

FTI Consulting

Ben Atwell/Ciara Martin - United Kingdom

[phone]

Sherryn Schooling - South Africa

[phone]

Registered address : 6^th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom

Website: www.mediclinic.com

Corporate broker (United Kingdom) : Morgan Stanley & Co International plc and UBS Investment Bank

JSE sponsor (South Africa): Rand Merchant Bank (A division of FirstRand Bank Limited)

NSX sponsor (Namibia): Simonis Storm Securities (Pty) Ltd

 

END

 

 

DSHBDGDIXDGDGDU